TY - RPRT T1 - Collaborative study for the establishment of the WHO 3rd international standard for Endotoxin, the Ph. Eur. endotoxin biological reference preparation batch 5 and the USP Reference Standard for Endotoxin Lot H0K354 Y1 - 2016 A1 - Findlay,L A1 - Desai,T. A1 - A. Heath A1 - Poole,S. A1 - Crivellonne,M. A1 - Hauxk,W. A1 - Ambrose,M. A1 - Morris,T. A1 - Daas,A. A1 - Rautmann,G. A1 - Buchheit,K.H. A1 - Spieser,J.M. A1 - Terao,E. KW - a KW - an KW - AS KW - at KW - Common KW - Control KW - differences KW - Endotoxins KW - Europe KW - European KW - global KW - health KW - healthcare KW - Institute KW - International KW - International Standard KW - IS KW - IT KW - Laboratories KW - Long-term KW - Medicine KW - medicines KW - method KW - methods KW - Objective KW - observed KW - organisation KW - organization KW - ph KW - PRODUCTS KW - Quality KW - Reference Standards KW - result KW - results KW - stability KW - STANDARD KW - standards KW - State KW - States KW - study KW - Temperature KW - TESTING KW - United States KW - use KW - WHO KW - world KW - World Health KW - World Health Organization KW - World-health-organization AB - An international collaborative study was organised jointly by the World Health Organization (WHO)/National Institute for Biological Standards and Control (NIBSC), the United StatesPharmacopeia (USP) and the European Directorate for the Quality of Medicines & HealthCare (EDQM/Council of Europe) for the establishment of harmonised replacement endotoxinstandards for these 3 organisations. Thirty-five laboratories worldwide, including Official Medicines Control Laboratories (OMCLs) and manufacturers enrolled in the study. Threecandidate preparations (10/178, 10/190 and 10/196) were produced with the same material and same formulation as the current reference standards with the objective of generating anew (3rd) International Standard (IS) with the same potency (10 000 IU/vial) as the current (2nd) IS, as well as new European Pharmacopoeia (Ph. Eur.). and USP standards. The suitability ofthe candidate preparations to act as the reference standard in assays for endotoxin performed according to compendial methods was evaluated. Their potency was calibrated against theWHO 2nd IS for Endotoxin (94/580). Gelation and photometric methods produced similar results for each of the candidate preparations. The overall potency estimates for the 3 batches werecomparable. Given the intrinsic assay precision, the observed differences between the batches may be considered unimportant for the intended use of these materials. Overall, these resultswere in line with those generated for the establishment of the current preparations of reference standards. Accelerated degradation testing of vials stored at elevated temperatures supportedthe long-term stability of the 3 candidate preparations.It was agreed between the 3 organisations that batch 10/178 be shared between WHO and EDQM and that batches 10/190 and 10/196 be allocated to USP, with a common assigned valueof 10 000 IU/vial. This value maintains the continuity of the global harmonisation of reference materials and unitage for the testing of endotoxins in parenteral pharmaceutical products. PB - EDQM CY - Strasbourg, France VL - Feb 2015 SN - 2075-2504 U1 - 5261 ER -